Champions Biotechnology, Inc. Launches PersonalizedCancerTreatment.com

Website Features Exclusive Personalized Cancer Treatment Options For Cancer
Patients And Healthcare Professionals

BALTIMORE, June 1 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC
Bulletin Board: CSBR), a company engaged in the development of advanced
preclinical platforms and tumor specific data to enhance the value of oncology
drugs, has launched the website PersonalizedCancerTreatment.com. The website
provides information and access to the company's unparalleled personalized
treatment options for physicians and their patients, including:

Personalized Tumorgraft(TM)

A Personalized Tumorgraft is a sample of the patient's living tumor that is
grown and tested in Champions' facilities. This novel approach optimizes
treatment choices through simultaneous evaluation of the effectiveness of
numerous anti-cancer drugs, sparing the patient from undergoing therapy that
may not be optimal for that specific cancer. Champions also maintains the
patient's living Tumorgraft to allow for future studies, if needed, for the
patient and his/her family.

Personalized Vaccine(TM)

A therapeutic cancer vaccine may be developed from the patient's tumor to
provide the most personalized cancer treatment available. Tumor cells from the
Personalized Tumorgraft are genetically modified, then used to stimulate a
patient's immune system to recognize and, if possible, attack the patient's
cancer cells.

Personalized Oncology Panel(TM)

Champions' provides the cancer patient and treating physician with access to
the world's top cancer experts, convening exclusive panels of renowned
experts, selected based on a patient's specific cancer type and condition,
from each of the disciplines critical to the patient's case. In a round table
forum, the expert panel debates the broad array of options and provides a
consensus treatment recommendation to the patient's physician.

The website also includes a selection of case presentations in the Healthcare
Professional section that demonstrate the positive clinical results achieved
by physicians whose cancer patients have chosen to use Champions' services.

"With the launch of our new website, Champions empowers Web users to explore,
learn, and expand their understanding of breakthrough cancer treatments,
making available today the personalized oncology options of tomorrow," said
Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "We are
providing patients and physicians with real-time access to cutting edge
medicine, including valuable insight into the most promising new cancer
treatments, genetic tests, novel therapeutics, landmark research, and more."

Dr. Burkett continued, "Champions offers a more precise approach to cancer
treatment, because every patient's cancer is unique. In partnership with one's
physician, Champions optimizes a given treatment plan's potential for success
and maximizes the patient's most precious resource: time. We anticipate the
launch of PersonalizedCancerTreatment.com will bring our exceptional spectrum
of personalized cancer treatment options to a broader audience than ever
before."

To learn more about Personalized Cancer Treatment please visit
www.personalizedcancertreatment.com.

For more news and information on Champions Biotechnology, Inc., please visit
www.IRGnews.com/coi/CSBR where you can find the CEO's video, a fact sheet on
the company, investor presentations, and more.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced
preclinical platforms and predictive tumor specific data to enhance and
accelerate the value of oncology drugs. The Company was co-founded by David
Sidransky, M.D. who with Manny Hidalgo, M.D., Ph.D. developed the Company's
Preclinical Platform; a novel approach based upon the implantation of primary
human tumors in immune deficient mice followed by propagation of the resulting
engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the
biological characteristics of the original human tumor. Early studies suggest
that these Tumorgrafts closely reflect human cancer biology and their response
to drugs is predictive of clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic candidates through
pre-clinical trials. As drugs progress through this early stage of
development, the Company plans to sell, partner or license them to
pharmaceutical and/or biotechnology companies, as appropriate. The Company
also offers its predictive preclinical platform and tumor specific data to
physicians for personalized patient care and to Companies for evaluation of
oncology drugs in models that integrate prognostic testing with biomarker
discovery.

Champions Biotechnology is dedicated to enhancing preclinical development
tools, accelerating development and valuation of oncology drugs, and advancing
personalized treatment with a goal to improve the lives of cancer patients
globally.

This press release contains "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect," "anticipate," "plan,"
and similar expressions to identify forward-looking statements. One should not
place undue reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the forward-looking
statements for many unforeseen factors. See Champions Biotechnology's Form
10-KSB for the fiscal year ended April 30, 2008 for a discussion of such
risks, uncertainties and other factors. Although the Company believes the
expectations reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity, performance or
achievements may not meet these expectations. The Company does not intend to
update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.

CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.com

SOURCE Champions Biotechnology, Inc.

James Carbonara, The Investor Relations Group, Inc., +1-212-825-3210 or Public
Relations: Susan Morgenbesser or Janet Vasquez, +1-212-825-3210